Tel Aviv, Tel Aviv District, Israel In 2004 was created Sphera Funds Management, which is appeared as VC. The venture was found in Asia in Israel. The leading representative office of defined VC is situated in the Tel Aviv.
Among the most popular fund investment industries, there are Health Care, Genetics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Passage Bio, GenSight Biologics, Oncorus The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The fund was created by Israel Mor. The overall number of key employees were 2.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The increased amount of exits for fund were in 2016. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Sphera Funds Management performs on 71 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations.
The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Sphera Funds Management, startups are often financed by Versant Ventures, OrbiMed, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Sanofi-Genzyme BioVentures, Perceptive Advisors. In the next rounds fund is usually obtained by Sofinnova Partners.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 13 Ventures | Charlottesville, United States, Virginia |
| African Development Bank | Belvédère, Tunis, Tunisia |
| AlleyCorp | New York, New York, United States |
| BluePointe Ventures | California, San Francisco, United States |
| Cassiopeia Capital Partners | Delaware, Lewes, United States |
| Ceres Partners | Indiana, South Bend, United States |
| CityRock Venture Partners | New York, New York, United States |
| CRS Recycling Services | - |
| First National Bank Of Omaha | Nebraska, Omaha, United States |
| FreeBit Co, Ltd | Chiyoda, Japan |
| Guosheng Group | China, Shanghai |
| Hybio Pharmaceutical | China, Guangdong, Shenzhen |
| Kardan | Amsterdam, Noord-Holland, The Netherlands |
| MoveTheDial | Canada, Ontario, Toronto |
| Mubadala Investment Company | California, San Francisco, United States |
| ODEWALD | Berlin, Berlin, Germany |
| Pomegranate Investment AB | - |
| VitaTech S.A | - |
| Waterloo Ventures | - |
| Zhejiang Daily Digital Culture | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ESCAPE Bio | $73M | 14 Sep 2020 | South San Francisco, California, United States | ||
C4 Therapeutics | $150M | 16 Jun 2020 | Cambridge, Massachusetts, United States | ||
Passage Bio | $110M | 04 Sep 2019 | Philadelphia, Pennsylvania, United States | ||
Oncorus | $79M | 21 Aug 2019 | Cambridge, Massachusetts, United States | ||
Stoke Therapeutics | $90M | 23 Oct 2018 | Massachusetts, United States | ||
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States | ||
GenSight Biologics | $36M | 23 Jul 2015 | Paris, Ile-de-France, France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ESCAPE Bio | $73M | 14 Sep 2020 | South San Francisco, California, United States | ||
C4 Therapeutics | $150M | 16 Jun 2020 | Cambridge, Massachusetts, United States | ||
Passage Bio | $110M | 04 Sep 2019 | Philadelphia, Pennsylvania, United States | ||
Oncorus | $79M | 21 Aug 2019 | Cambridge, Massachusetts, United States | ||
Stoke Therapeutics | $90M | 23 Oct 2018 | Massachusetts, United States | ||
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States | ||
GenSight Biologics | $36M | 23 Jul 2015 | Paris, Ile-de-France, France |
